iPSC technology-based regenerative therapy for diabetes.

iPSC technology-based regenerative therapy for diabetes.
复制标题

DOI:
10.1111/jdi.12702
复制
发表时间:
2018-03
影响因子:
3.2
通讯作者:
Osafune K
Osafune K
中科院分区:
医学3区
文献类型:
--
作者:
Kondo Y;Toyoda T;Inagaki N;Osafune K

文献摘要

参考文献

被引文献

相似文献

人类多能干细胞,如胚胎干细胞(hESCs)和诱导多能干细胞(hiPSCs),定向分化为胰腺内分泌谱系,已经通过复制胰腺的体内发育过程进行了大量研究。该研究领域的最新进展使hESCs/iPSCs在体外产生功能成熟的β样细胞,这些细胞具有葡萄糖反应性胰岛素分泌能力。利用糖尿病动物模型评估了hESC/iPSC衍生胰腺细胞的治疗潜力,并研究了包括免疫保护装置在内的移植方法,以防止宿主对植入胰腺细胞的免疫反应,从而开发针对糖尿病的再生疗法。这些努力导致了一项临床试验的开始,该试验涉及将hESC来源的胰腺祖细胞植入1型糖尿病患者。此外,患者来源的iPSCs已经从糖尿病相关疾病中产生,用于创建新的体外疾病模型和药物发现,尽管迄今为止很少有报道分析疾病机制。考虑到产生胰腺内分泌谱系的分化方法的最新进展,我们将在未来十年看到基于iPSC技术研究的新型细胞疗法和治疗糖尿病的药物的发展。
The directed differentiation of human pluripotent stem cells, such as embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs), into pancreatic endocrine lineages has been vigorously examined by reproducing the in vivo developmental processes of the pancreas. Recent advances in this research field have enabled the generation from hESCs/iPSCs of functionally mature β‐like cells in vitro that show glucose‐responsive insulin secretion ability. The therapeutic potentials of hESC/iPSC‐derived pancreatic cells have been evaluated using diabetic animal models, and transplantation methods including immunoprotective devices that prevent immune responses from hosts to the implanted pancreatic cells have been investigated towards the development of regenerative therapies against diabetes. These efforts led to the start of a clinical trial that involves the implantation of hESC‐derived pancreatic progenitors into type 1 diabetes patients. In addition, patient‐derived iPSCs have been generated from diabetes‐related disorders towards the creation of novel in vitro disease models and drug discovery, although few reports so far have analyzed the disease mechanisms. Considering recent advances in differentiation methods that generate pancreatic endocrine lineages, we will see the development of novel cell therapies and therapeutic drugs against diabetes based on iPSC technology‐based research in the next decade.
DOI: 10.5966/sctm.2015-0079
发表时间: 2015-10-01
影响因子: 6
作者:
Agulnick, Alan D.;Ambruzs, Dana M.;D'Amour, Kevin A.
通讯作者: D'Amour, Kevin A.
DOI: 10.3727/096368914x685762
发表时间: 2015
影响因子: 3.3
作者:
Kikuchi C;Bienengraeber M;Canfield S;Koopmeiner A;Schäfer R;Bosnjak ZJ;Bai X
通讯作者: Bai X
DOI: 10.1097/aln.0b013e3182655e96
发表时间: 2012-10
期刊: Anesthesiology
影响因子: 8.8
作者:
Canfield SG;Sepac A;Sedlic F;Muravyeva MY;Bai X;Bosnjak ZJ
通讯作者: Bosnjak ZJ
DOI: 10.1016/j.celrep.2012.10.022
发表时间: 2012-12-01
期刊: CELL REPORTS
影响因子: 8.8
作者:
Huang, Yali;Osorno, Rodrigo;Wilson, Valerie
通讯作者: Wilson, Valerie
DOI: 10.5966/sctm.2011-0044
发表时间: 2012-06-01
影响因子: 6
作者:
Kudva, Yogish C.;Ohmine, Seiga;Ikeda, Yasuhiro
通讯作者: Ikeda, Yasuhiro